200 related articles for article (PubMed ID: 7560201)
1. Apocrine adenosis: a precursor of aggressive breast cancer?
Wells CA; McGregor IL; Makunura CN; Yeomans P; Davies JD
J Clin Pathol; 1995 Aug; 48(8):737-42. PubMed ID: 7560201
[TBL] [Abstract][Full Text] [Related]
2. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
Selim AG; El-Ayat G; Wells CA
Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
[TBL] [Abstract][Full Text] [Related]
3. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
Celis JE; Moreira JM; Gromova I; Cabezón T; Gromov P; Shen T; Timmermans V; Rank F
Mol Oncol; 2007 Jun; 1(1):97-119. PubMed ID: 19383289
[TBL] [Abstract][Full Text] [Related]
4. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
5. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
Elayat G; Selim AG; Wells CA
Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
[TBL] [Abstract][Full Text] [Related]
6. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
7. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
8. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up.
Seidman JD; Ashton M; Lefkowitz M
Cancer; 1996 Jun; 77(12):2529-37. PubMed ID: 8640702
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of E-cadherin in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Facina G; Lopes-Costa PV; Dos Santos AR; De Vasconcelos-Valença RJ; Pinho-Sobral AL; Ferreira-Filho CP; Alencar AP; Gebrim LH; Da Silva BB
Diagn Cytopathol; 2010 Apr; 38(4):235-8. PubMed ID: 19790246
[TBL] [Abstract][Full Text] [Related]
10. Atypical Apocrine Adenosis: Diagnostic Challenges and Pitfalls.
Asirvatham JR; Falcone MM; Kleer CG
Arch Pathol Lab Med; 2016 Oct; 140(10):1045-51. PubMed ID: 27684975
[TBL] [Abstract][Full Text] [Related]
11. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
13. The Histologic Spectrum of Apocrine Lesions of the Breast.
Durham JR; Fechner RE
Am J Clin Pathol; 2000 May; 113(suppl_1):S3-18. PubMed ID: 11993707
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 tumor suppressor gene, oncoprotein c-erbB-2, cellular proliferation and differentiation in malignant and benign pancreatic lesions.
Jaskiewicz K; Krige JE; Thomson J
Anticancer Res; 1994; 14(5A):1919-22. PubMed ID: 7847827
[TBL] [Abstract][Full Text] [Related]
15. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
16. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
17. Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: report of a case.
Visscher DW
Arch Pathol Lab Med; 2009 Nov; 133(11):1817-21. PubMed ID: 19886717
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
19. Surgical follow-up results for apocrine adenosis and atypical apocrine adenosis diagnosed on breast core biopsy.
Hou Y; Chaudhary S; Gao FF; Li Z
Ann Diagn Pathol; 2016 Oct; 24():4-6. PubMed ID: 27649945
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
